Elite retired rowers face a nearly threefold increased risk of atrial fibrillation compared to the general population, driven ...

A new study involving 121 former elite rowers from Australia has revealed one in five develops atrial fibrillation (AFib).

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)’s Complete Response Letter (CRL) regarding its New Drug ...

MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete ...

Milestone is on track to initiate a Phase 3 trial evaluating etripamil in AFib-RVR in 2025. The protocol of a Phase 3, potentially registrational study has been finalized and study start-up has ...

FARMERSBURG, Ind. (WTWO/WAWV) — When it comes to heart health, the prevalence of a condition shouldn’t be much of a comfort for those dealing with symptoms. While it’s always good to kn… ...

Phase 3 pivotal trial in AFib-RVR expected to begin enrollment in H1 2025. Milestone plans to initiate a trial of etripamil nasal spray in patients with AFib-RVR in the at-home setting.

CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 ...

However, doctors categorize a heart rate above 120 bpm as AFib with rapid ventricular response. In these cases, doctors may use treatments that include cardioversion and an intravenous (IV ...

Atrial fibrillation with rapid ventricular response is a fancy name for an irregular heartbeat. When your heart 's electrical signals aren't working right, it can lead to a heartbeat that's too fast.

Background: Patients presenting with new onset atrial fibrillation with rapid ventricular response (AFRVR) may present with a reduced left ventricular ejection fraction (LVEF). We hypothesized that ...

MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of ...